Protagonist Therapeutics
PTGX
77 hedge funds and large institutions have $165M invested in Protagonist Therapeutics in 2020 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 31 increasing their positions, 28 reducing their positions, and 9 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 28
1% more capital invested
Capital invested by funds: $164M → $165M (+$1.52M)
0.41% more ownership
Funds ownership: 85.25% → 85.66% (+0.41%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 81 → 77 (-4)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$4.68M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$3.78M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$1.64M |
| 4 |
RI
RTW Investments
New York
|
+$1.5M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$636K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.78M |
| 2 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$1.76M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.12M |
| 4 |
O
OrbiMed
New York
|
-$931K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$779K |
PTGX Hedge Fund Activity: Q1 2020 in Review
77 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q1 2020, worth a combined $165M — up 0.93% from $164M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PTGX and 8 opened new positions — a net loss of 1 holder — while 28 trimmed existing stakes and 31 added.
The largest buyer was JP Morgan Chase, adding an estimated $4.68M. The largest seller was Millennium Management, cutting an estimated $3.78M.
- 77 institutional investors held Protagonist Therapeutics (PTGX) as of Q1 2020, down from 81 in Q4 2019.
- Funds reported $165M of Protagonist Therapeutics stock for Q1 2020, up 0.93% quarter-over-quarter.
- 8 funds opened new Protagonist Therapeutics positions in Q1 2020 and 9 closed out, a net change of -1 holder.
- The largest Protagonist Therapeutics buyer in Q1 2020 was JP Morgan Chase, an estimated $4.68M added.
- The largest Protagonist Therapeutics seller in Q1 2020 was Millennium Management, an estimated $3.78M sold.
Based on aggregated 13F filings for Q1 2020.